Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T00140
|
||||
Former ID |
TTDS00112
|
||||
Target Name |
Arachidonate 5-lipoxygenase
|
||||
Gene Name |
ALOX5
|
||||
Synonyms |
5-LO; 5-LOX; 5-lipoxygenase; ALOX5
|
||||
Target Type |
Successful
|
||||
Disease | Arthritis [ICD9: 710-719; ICD10: M00-M25] | ||||
Allergy [ICD9: 995.3; ICD10: T78.4] | |||||
Atherosclerosis [ICD9: 414.0, 440; ICD10: I70] | |||||
Asthma [ICD10: J45] | |||||
Atopic dermatitis [ICD9: 691.8, 692.9; ICD10: L00-L99] | |||||
Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10: J40-J44, J47] | |||||
Dermatitis [ICD9: 692.9; ICD10: L20-L30] | |||||
Fungal infections [ICD9: 110-118; ICD10: B35-B49] | |||||
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25] | |||||
Inflammation [ICD10: E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89] | |||||
Lymphatic filariasis [ICD9: 125; ICD10: B74] | |||||
Osteoarthritis [ICD9: 715; ICD10: M15-M19, M47] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Pruritus [ICD9: 698; ICD10: L29] | |||||
Respiratory disease [ICD10: J00-J99] | |||||
Rhinitis [ICD9: 472.0, 477; ICD10: J00, J30, J31.0] | |||||
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10: I80-I82] | |||||
Unspecified [ICD code not available] | |||||
Function |
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
|
||||
BioChemical Class |
Oxidoreductases acting on single donors
|
||||
Target Validation |
T00140
|
||||
UniProt ID | |||||
EC Number |
EC 1.13.11.34
|
||||
Sequence |
MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDE
ELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLA RDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVL NYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNG CNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDP CTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDF HVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECG LFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWE AIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYL TVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCW HLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPY YYLSPDRIPNSVAI |
||||
Drugs and Mode of Action | |||||
Drug(s) | Diethylcarbamazine | Drug Info | Approved | Lymphatic filariasis | [536135], [551871] |
Zileuton | Drug Info | Approved | Asthma | [536528], [540757] | |
Silymarin | Drug Info | Phase 4 | Discovery agent | [521938] | |
ABT-761 | Drug Info | Phase 3 | Asthma | [526129] | |
Flobufen | Drug Info | Phase 3 | Rheumatoid arthritis | [534411] | |
FPL-62064 | Drug Info | Phase 3 | Inflammation | [531310] | |
TENIDAP | Drug Info | Phase 3 | Rheumatoid arthritis | [529470], [539523] | |
Darbufelone | Drug Info | Phase 2/3 | Asthma | [532278] | |
CMI-392 | Drug Info | Phase 2 | Psoriasis | [526130] | |
E-6700 | Drug Info | Phase 2 | Asthma | [534187] | |
MK-866 | Drug Info | Phase 2 | Unspecified | [1560455] | |
PF-4191834 | Drug Info | Phase 2 | Asthma | [523080] | |
Rilopirox | Drug Info | Phase 2 | Fungal infections | [546060] | |
SK&F 86002 | Drug Info | Phase 2 | Rheumatoid arthritis | [534089], [541296] | |
TA-270 | Drug Info | Phase 2 | Asthma | [546872] | |
Tepoxalin | Drug Info | Phase 2 | Asthma | [534424] | |
Tipelukast | Drug Info | Phase 2 | Asthma | [525273] | |
UCB-35440 | Drug Info | Phase 2 | Rhinitis | [549930] | |
WY-50295-tromethamine | Drug Info | Phase 2 | Asthma | [525487] | |
BF-389 | Drug Info | Phase 1 | Rheumatoid arthritis | [526850] | |
SKF-105809 | Drug Info | Phase 1 | Pain | [529852] | |
Ibuproxam | Drug Info | Withdrawn from market | Respiratory disease | [533573] | |
Lonapalene | Drug Info | Discontinued in Phase 3 | Psoriasis | [545588] | |
CJ-13610 | Drug Info | Discontinued in Phase 2 | Asthma | [468230], [536223] | |
CV-6504 | Drug Info | Discontinued in Phase 2 | Discovery agent | [545370] | |
DuP-654 | Drug Info | Discontinued in Phase 2 | Pruritus | [545553] | |
E-3040 | Drug Info | Discontinued in Phase 2 | Thrombosis | [546036] | |
E-6080 | Drug Info | Discontinued in Phase 2 | Asthma | [545041] | |
ETH615 | Drug Info | Discontinued in Phase 2 | Dermatitis | [546166] | |
FPL-64170 | Drug Info | Discontinued in Phase 2 | Psoriasis | [545854] | |
Linetastine | Drug Info | Discontinued in Phase 2 | Rhinitis | [545155] | |
MK-591 | Drug Info | Discontinued in Phase 2 | Asthma | [544955] | |
MK-886 | Drug Info | Discontinued in Phase 2 | Asthma | [539722], [544532] | |
MLN-977 | Drug Info | Discontinued in Phase 2 | Chronic obstructive pulmonary disease | [546341] | |
R-68151 | Drug Info | Discontinued in Phase 2 | Psoriasis | [545537] | |
SC-45662 | Drug Info | Discontinued in Phase 2 | Asthma | [544863] | |
TEBUFELONE | Drug Info | Discontinued in Phase 2 | Pain | [545171] | |
AZD-4407 | Drug Info | Discontinued in Phase 1 | Chronic obstructive pulmonary disease | [546713] | |
CD-581 | Drug Info | Discontinued in Phase 1 | Atopic dermatitis | [546435] | |
Licofelone | Drug Info | Discontinued in Phase 1 | Osteoarthritis | [545621] | |
A-78773 | Drug Info | Terminated | Asthma | [545524] | |
A-79175 | Drug Info | Terminated | Asthma | [545797] | |
A-80263 | Drug Info | Terminated | Inflammatory disease | [545528] | |
AA-861 | Drug Info | Terminated | Allergy | [544544] | |
BI-L-357 | Drug Info | Terminated | Asthma | [545110] | |
BU-4601A | Drug Info | Terminated | Asthma | [545892] | |
BW A4C | Drug Info | Terminated | Arthritis | [544587] | |
BW B70C | Drug Info | Terminated | Asthma | [545111] | |
BW755C | Drug Info | Terminated | Inflammatory disease | [534109] | |
CGS 8515 | Drug Info | Terminated | Discovery agent | [545304] | |
CGS-26529 | Drug Info | Terminated | Inflammatory disease | [546004] | |
CI-986 | Drug Info | Terminated | Rheumatoid arthritis | [525669] | |
CMI-206 | Drug Info | Terminated | Inflammatory disease | [551572] | |
Epocarbazolin-A | Drug Info | Terminated | Asthma | [534037] | |
ER-34122 | Drug Info | Terminated | Inflammatory disease | [526240], [534759] | |
KC-11404 | Drug Info | Terminated | Asthma | [533776] | |
KC-11425 | Drug Info | Terminated | Asthma | [545947] | |
LY-221068 | Drug Info | Terminated | Arthritis | [545172] | |
NAFAZATROM | Drug Info | Terminated | Discovery agent | [544529] | |
PD-146176 | Drug Info | Terminated | Atherosclerosis | [546784] | |
R zileuton | Drug Info | Terminated | Asthma | [548595] | |
R-85355 | Drug Info | Terminated | Discovery agent | [545061] | |
REV-5901 | Drug Info | Terminated | Discovery agent | [544591] | |
RWJ-63556 | Drug Info | Terminated | Arthritis | [534446] | |
Sch-40120 | Drug Info | Terminated | Pruritus | [545555] | |
SKF-104351 | Drug Info | Terminated | Rheumatoid arthritis | [544770] | |
WY-28342 | Drug Info | Terminated | Rheumatoid arthritis | [545972] | |
ZD-7717 | Drug Info | Terminated | Asthma | [546302] | |
ZM-230487 | Drug Info | Terminated | Asthma | [545870] | |
Inhibitor | 1,2-Dihydro-indazol-3-one | Drug Info | [529474] | ||
1,2-Dihydroxy-10H-anthracen-9-one | Drug Info | [534507] | |||
1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one | Drug Info | [534507] | |||
1,5-Dihydroxy-10H-anthracen-9-one | Drug Info | [534507] | |||
1,8,9-Trimethoxy-9,10-dihydro-anthracene | Drug Info | [534507] | |||
1,8-Dichloro-10H-anthracen-9-one | Drug Info | [534507] | |||
1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one | Drug Info | [534507] | |||
1-Benzyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3) | Drug Info | [536971] | |||
1-Hydroxy-10H-anthracen-9-one | Drug Info | [534507] | |||
1-Hydroxy-8-methoxy-10H-anthracen-9-one | Drug Info | [534507] | |||
1-Methyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one | Drug Info | [534507] | |||
10-Benzoyl-1,8-dihydroxy-10H-anthracen-9-one | Drug Info | [534507] | |||
15-hydroxyeicosatetraenoic acid | Drug Info | [535027], [538140] | |||
2'-Nitro-biphenyl-4-carboxylic acid hydroxyamide | Drug Info | [532087] | |||
2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide | Drug Info | [532087] | |||
2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide | Drug Info | [532087] | |||
2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide | Drug Info | [532087] | |||
2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide | Drug Info | [532087] | |||
2-(4-hydroxylphenyl)-3-(3,5-dihydroxylphenyl) propenoic acid (NNU-hdpa) | Drug Info | [537200] | |||
2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol | Drug Info | [531065] | |||
2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Benzyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide | Drug Info | [532087] | |||
2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Methyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Phenethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Phenyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Pyridin-3-ylmethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one | Drug Info | [529474] | |||
3,4-Dihydroxy-10H-anthracen-9-one | Drug Info | [534507] | |||
3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide | Drug Info | [532087] | |||
3-Benzoyl-N-hydroxy-benzamide | Drug Info | [532087] | |||
3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide | Drug Info | [532087] | |||
3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide | Drug Info | [532087] | |||
4,5-Dihydroxy-10H-anthracen-9-one | Drug Info | [534507] | |||
4,5-Dimethoxy-10H-anthracen-9-one | Drug Info | [534507] | |||
4-(1H-indol-3-yl)-1-morpholinobutan-1-one | Drug Info | [528710] | |||
4-Bromo-N-hydroxy-benzamide | Drug Info | [532087] | |||
4-Butoxy-N-hydroxy-N-methyl-benzamide | Drug Info | [532087] | |||
4-Hydroxy-5-methoxy-10H-anthracen-9-one | Drug Info | [534507] | |||
4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid | Drug Info | [532133] | |||
5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine | Drug Info | [531178] | |||
5-Chloro-N-phenylbenzo[d]oxazol-2-amine | Drug Info | [531178] | |||
5-Hydroxyeicosatetraenoic acid | Drug Info | [535027], [538140] | |||
5-Methoxy-N-phenylbenzo[d]oxazol-2-amine | Drug Info | [531178] | |||
5-Methyl-2-p-tolyl-thiazol-4-ol | Drug Info | [531065] | |||
5-Methyl-N-phenylbenzo[d]oxazol-2-amine | Drug Info | [531178] | |||
7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) | Drug Info | [536698] | |||
A-78773 | Drug Info | [534630] | |||
A-79175 | Drug Info | [537871], [538075] | |||
A-80263 | Drug Info | [550844] | |||
AA-861 | Drug Info | [536343], [536532], [536917], [537748] | |||
ABT-761 | Drug Info | [530760], [534862], [535369] | |||
ACACETIN | Drug Info | [525606] | |||
Acanthus ilicifolius Linn | Drug Info | [536815] | |||
Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester | Drug Info | [531065] | |||
Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester | Drug Info | [531065] | |||
Anthracene-2-carboxylic acid hydroxyamide | Drug Info | [532087] | |||
ANTHRONE | Drug Info | [534507] | |||
AZD-4407 | Drug Info | [532630] | |||
BAICALEIN | Drug Info | [529474] | |||
BI-L-357 | Drug Info | [534012] | |||
Biphenyl-3-carboxylic acid hydroxyamide | Drug Info | [532087] | |||
Biphenyl-4-carboxylic acid hydroxyamide | Drug Info | [532087] | |||
BU-4601A | Drug Info | [534063] | |||
BUDDLEDIN A | Drug Info | [525606] | |||
BW A360C | Drug Info | [536518] | |||
BW A4C | Drug Info | [536189], [536518], [537431] | |||
BW B218C | Drug Info | [536518] | |||
BW B70C | Drug Info | [536518] | |||
BW755C | Drug Info | [536815] | |||
Caffeic acid | Drug Info | [535256], [536714], [536829] | |||
CD-581 | Drug Info | [551871] | |||
CGS 8515 | Drug Info | [537697] | |||
CGS-26529 | Drug Info | [534079] | |||
Chebulagic acid | Drug Info | [537395] | |||
CJ-13610 | Drug Info | [536223] | |||
CV-6504 | Drug Info | [535071], [537655] | |||
CYLINDOL A | Drug Info | [551361] | |||
Diethylcarbamazine | Drug Info | [534910] | |||
DuP-654 | Drug Info | [534020] | |||
E-3040 | Drug Info | [526097] | |||
E-6080 | Drug Info | [526797] | |||
Epocarbazolin-A | Drug Info | [534037] | |||
ETH615 | Drug Info | [535027] | |||
FPL-64170 | Drug Info | [534226] | |||
Fuscoside | Drug Info | [535802] | |||
Heme | Drug Info | [551374] | |||
Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester | Drug Info | [531065] | |||
Hyperforin | Drug Info | [535615] | |||
Ibuproxam | Drug Info | [533474] | |||
ICI 207968 | Drug Info | [536189] | |||
JUGLONE | Drug Info | [534507] | |||
L-652,343 | Drug Info | [537735] | |||
Licofelone | Drug Info | [535517], [536541], [536548], [536629] | |||
Linetastine | Drug Info | [535027], [538079] | |||
Lonapalene | Drug Info | [535027], [537662] | |||
LY-221068 | Drug Info | [529094] | |||
MK-591 | Drug Info | [537895], [538006] | |||
MLN-977 | Drug Info | [544446] | |||
N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine | Drug Info | [531178] | |||
N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine | Drug Info | [531178] | |||
N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine | Drug Info | [531178] | |||
N-(4-Ethylphenyl)benzo[d]oxazol-2-amine | Drug Info | [531178] | |||
N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-2-naphthalen-2-yl-acetamide | Drug Info | [532087] | |||
N-Hydroxy-3-naphthalen-2-yl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-3-naphthalen-2-yl-propionamide | Drug Info | [532087] | |||
N-Hydroxy-3-phenyl-acrylamide | Drug Info | [532087] | |||
N-hydroxy-4-(naphthalen-1-yl)benzamide | Drug Info | [532087] | |||
N-Hydroxy-4-iodo-benzamide | Drug Info | [532087] | |||
N-Hydroxy-4-isobutyl-benzamide | Drug Info | [532087] | |||
N-Hydroxy-4-naphthalen-2-yl-benzamide | Drug Info | [532087] | |||
N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide | Drug Info | [532087] | |||
N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide | Drug Info | [533474] | |||
N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide | Drug Info | [532087] | |||
N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide | Drug Info | [532087] | |||
N-Hydroxy-N-methyl-benzamide | Drug Info | [532087] | |||
N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea | Drug Info | [534335] | |||
N-Phenylbenzo[d]oxazol-2-amine | Drug Info | [531178] | |||
NAFAZATROM | Drug Info | [532133] | |||
Naphthalene-2-carboxylic acid hydroxyamide | Drug Info | [532087] | |||
NAPHTHAZALIN | Drug Info | [534507] | |||
PF-4191834 | Drug Info | [530836] | |||
Phenanthrene-2-carboxylic acid hydroxyamide | Drug Info | [532087] | |||
Phenanthrene-3-carboxylic acid hydroxyamide | Drug Info | [532087] | |||
PHENIDONE | Drug Info | [551361] | |||
PYROGALLOL | Drug Info | [534507] | |||
R zileuton | Drug Info | [526854] | |||
R-68151 | Drug Info | [535027], [538009] | |||
R-85355 | Drug Info | [538009] | |||
REV-5901 | Drug Info | [529474] | |||
Rilopirox | Drug Info | [529413] | |||
SC-45662 | Drug Info | [528836] | |||
Silymarin | Drug Info | [534984] | |||
SK&F 107649 | Drug Info | [537907] | |||
SK&F 86002 | Drug Info | [537659] | |||
SKF-105809 | Drug Info | [529852] | |||
TA-270 | Drug Info | [526720] | |||
TEBUFELONE | Drug Info | [534599] | |||
Tepoxalin | Drug Info | [537990] | |||
TZI-41127 | Drug Info | [551270] | |||
WY-50295-tromethamine | Drug Info | [525487] | |||
Zileuton | Drug Info | [535027], [535474], [536892], [536901], [537073], [537169] | |||
ZM-230487 | Drug Info | [536489] | |||
Modulator | BF-389 | Drug Info | [526850] | ||
BW-858C | Drug Info | [534049] | |||
BW-A137C | Drug Info | ||||
CGS-23885 | Drug Info | ||||
CI-986 | Drug Info | [525669] | |||
CMI-206 | Drug Info | ||||
CMI-392 | Drug Info | [526130] | |||
Darbufelone | Drug Info | [532278] | |||
E-6700 | Drug Info | [534187] | |||
ER-34122 | Drug Info | [526240], [534759] | |||
Flobufen | Drug Info | [534411] | |||
FPL-62064 | Drug Info | [531310] | |||
FR-122788 | Drug Info | ||||
ICI-211965 | Drug Info | ||||
KC-11404 | Drug Info | [533776] | |||
MK-866 | Drug Info | ||||
MK-886 | Drug Info | ||||
PD-146176 | Drug Info | ||||
RWJ-63556 | Drug Info | [534446] | |||
SB-202235 | Drug Info | ||||
SC-41661A | Drug Info | ||||
Sch-40120 | Drug Info | [526810] | |||
SKF-104351 | Drug Info | [550942] | |||
TENIDAP | Drug Info | [529470] | |||
Tipelukast | Drug Info | ||||
UCB-35440 | Drug Info | [527359] | |||
WY-28342 | Drug Info | [533715] | |||
ZD-7717 | Drug Info | [550946] | |||
Antagonist | KC-11425 | Drug Info | [551926] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
Resolvin D biosynthesis | |||||
Leukotriene biosynthesis | |||||
Lipoxin biosynthesis | |||||
Aspirin triggered resolvin D biosynthesis | |||||
Aspirin triggered resolvin E biosynthesis | |||||
KEGG Pathway | Arachidonic acid metabolism | ||||
Metabolic pathways | |||||
Serotonergic synapse | |||||
Ovarian steroidogenesis | |||||
Toxoplasmosis | |||||
NetPath Pathway | IL4 Signaling Pathway | ||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
WikiPathways | Vitamin D Receptor Pathway | ||||
Arachidonic acid metabolism | |||||
Eicosanoid Synthesis | |||||
Selenium Micronutrient Network | |||||
References | |||||
Ref 468230 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5169). | ||||
Ref 521938 | ClinicalTrials.gov (NCT00412763) Efficacy of Silymarin for Acute Hepatitis. U.S. National Institutes of Health. | ||||
Ref 523080 | ClinicalTrials.gov (NCT01147458) A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee. U.S. National Institutes of Health. | ||||
Ref 525273 | ClinicalTrials.gov (NCT02503657) Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF). | ||||
Ref 525487 | WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood. Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):31-41. | ||||
Ref 525669 | Role of leukotrienes on coronary vasoconstriction in isolated hearts of arthritic rats: effect of in vivo treatment with CI-986, a dual inhibitor of cyclooxygenase and lipoxygenase. Pharmacology. 2000 Jan;60(1):41-6. | ||||
Ref 526130 | Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20. | ||||
Ref 526240 | Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci. 2002 Jan;91(1):258-66. | ||||
Ref 526850 | Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions. 1992 Sep;37(1-2):90-8. | ||||
Ref 529470 | The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3. | ||||
Ref 529852 | Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7. | ||||
Ref 531310 | FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42. | ||||
Ref 532278 | Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9. | ||||
Ref 533573 | Anti-inflammatory agents: determination of ibuproxam and its metabolite humans. Correlation between bioavailability, tolerance and chemico-physical characteristics. Arzneimittelforschung. 1980;30(9):1607-9. | ||||
Ref 533776 | Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. J Med Chem. 1995 Feb 17;38(4):669-85. | ||||
Ref 534037 | Epocarbazolins A and B, novel 5-lipoxygenase inhibitors. Taxonomy, fermentation, isolation, structures and biological activities. J Antibiot (Tokyo). 1993 Jan;46(1):25-33. | ||||
Ref 534089 | The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. Inflamm Res. 1995 Jul;44(7):269-74. | ||||
Ref 534109 | BW755C, a dual lipoxygenase/cyclooxygenase inhibitor, reduces mural platelet and neutrophil deposition and vasoconstriction after angioplasty injury in pigs. J Pharmacol Exp Ther. 1996 Apr;277(1):17-21. | ||||
Ref 534187 | Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57. | ||||
Ref 534411 | Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52. | ||||
Ref 534424 | Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids. 1997 Jun;56(6):417-23. | ||||
Ref 534446 | Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101. | ||||
Ref 534759 | ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Inflamm Res. 1998 Oct;47(10):375-83. | ||||
Ref 536135 | Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. | ||||
Ref 536223 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | ||||
Ref 536528 | Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46. | ||||
Ref 539523 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2395). | ||||
Ref 539722 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2655). | ||||
Ref 540757 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5297). | ||||
Ref 541296 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6040). | ||||
Ref 544529 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000069) | ||||
Ref 544532 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000073) | ||||
Ref 544544 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000099) | ||||
Ref 544587 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000230) | ||||
Ref 544591 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000242) | ||||
Ref 544770 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000933) | ||||
Ref 544863 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001362) | ||||
Ref 544955 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001712) | ||||
Ref 545041 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001952) | ||||
Ref 545061 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001998) | ||||
Ref 545110 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002162) | ||||
Ref 545111 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002163) | ||||
Ref 545155 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002311) | ||||
Ref 545171 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002346) | ||||
Ref 545172 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002348) | ||||
Ref 545304 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002765) | ||||
Ref 545370 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003054) | ||||
Ref 545524 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003598) | ||||
Ref 545528 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003607) | ||||
Ref 545537 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003630) | ||||
Ref 545553 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003690) | ||||
Ref 545555 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003693) | ||||
Ref 545588 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003802) | ||||
Ref 545621 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003927) | ||||
Ref 545797 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004773) | ||||
Ref 545854 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005063) | ||||
Ref 545870 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005134) | ||||
Ref 545892 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005261) | ||||
Ref 545947 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005461) | ||||
Ref 545972 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005582) | ||||
Ref 546004 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005833) | ||||
Ref 546036 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005994) | ||||
Ref 546060 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006112) | ||||
Ref 546166 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006733) | ||||
Ref 546302 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007338) | ||||
Ref 546341 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007577) | ||||
Ref 546435 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008118) | ||||
Ref 546713 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009803) | ||||
Ref 546784 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010267) | ||||
Ref 546872 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010788) | ||||
Ref 548595 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026867) | ||||
Ref 551572 | Cmi206: A potent dual platelet activating factor antagonist and 5-lipoxygenase inhibitor. Bioorganic & Medicinal Chemistry Letters. 03/1995; 5(6):643-648. | ||||
Ref 525487 | WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood. Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):31-41. | ||||
Ref 525606 | J Nat Prod. 1999 Sep;62(9):1241-5.Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. | ||||
Ref 525669 | Role of leukotrienes on coronary vasoconstriction in isolated hearts of arthritic rats: effect of in vivo treatment with CI-986, a dual inhibitor of cyclooxygenase and lipoxygenase. Pharmacology. 2000 Jan;60(1):41-6. | ||||
Ref 526097 | In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production. Eur J Pharmacol. 2001 Jun 22;422(1-3):209-16. | ||||
Ref 526130 | Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20. | ||||
Ref 526240 | Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci. 2002 Jan;91(1):258-66. | ||||
Ref 526720 | TA-270 [4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], an anti-asthmatic agent, inhibits leukotriene production induced by IgE receptor stimulation in RBL-2H3 cells. J Pharmacol Exp Ther. 2003 Nov;307(2):583-8. Epub 2003 Sep 11. | ||||
Ref 526797 | Effects of the new 5-lipoxygenase inhibitor E6080 on leukotriene release in vitro. Int Arch Allergy Immunol. 1992;97(4):267-73. | ||||
Ref 526810 | Actions of a 5-lipoxygenase inhibitor, Sch 40120, on acute inflammatory responses. J Pharmacol Exp Ther. 1992 Aug;262(2):721-8. | ||||
Ref 526850 | Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions. 1992 Sep;37(1-2):90-8. | ||||
Ref 526854 | Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60. | ||||
Ref 527359 | The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol. 2005 Jan 4;506(3):265-71. Epub 2004 Dec 1. | ||||
Ref 528710 | Bioorg Med Chem Lett. 2007 May 1;17(9):2414-20. Epub 2007 Feb 17.Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling. | ||||
Ref 528836 | The immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45662). Transplantation. 1991 Dec;52(6):1053-7. | ||||
Ref 529094 | Anti-inflammatory effects of LY221068 and LY269415. Agents Actions. 1991 Sep;34(1-2):100-2. | ||||
Ref 529413 | Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect. Mycoses. 1991;34 Suppl 1:91-3. | ||||
Ref 529470 | The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3. | ||||
Ref 529474 | J Med Chem. 1991 Mar;34(3):1028-36.Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. | ||||
Ref 529852 | Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7. | ||||
Ref 530760 | Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307. | ||||
Ref 530836 | Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther. 2010 Jul;334(1):294-301. | ||||
Ref 531178 | Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. Epub 2010 Oct 1.Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. | ||||
Ref 531310 | FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42. | ||||
Ref 532087 | J Med Chem. 1990 Mar;33(3):992-8.Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. | ||||
Ref 532133 | J Med Chem. 1990 Apr;33(4):1163-70.Design, synthesis, and 5-lipoxygenase-inhibiting properties of 1-thio-substituted butadienes. | ||||
Ref 532278 | Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9. | ||||
Ref 532630 | Palladium catalyzed aryl(alkyl)thiolation of unactivated arenes. Org Lett. 2014 Feb 7;16(3):848-51. | ||||
Ref 533474 | J Med Chem. 1987 Nov;30(11):2121-6.In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. | ||||
Ref 533715 | Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. J Med Chem. 1995 Apr 28;38(9):1473-81. | ||||
Ref 533776 | Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. J Med Chem. 1995 Feb 17;38(4):669-85. | ||||
Ref 534012 | A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor. J Pharmacol Exp Ther. 1993 May;265(2):483-9. | ||||
Ref 534020 | The lipoxygenase inhibitor 2-phenylmethyl-1-naphthol (DuP 654) is a 12(S)-hydroxyeicosatetraenoic acid receptor antagonist in the human epidermal cell line SCL-II. Skin Pharmacol. 1993;6(2):148-51. | ||||
Ref 534037 | Epocarbazolins A and B, novel 5-lipoxygenase inhibitors. Taxonomy, fermentation, isolation, structures and biological activities. J Antibiot (Tokyo). 1993 Jan;46(1):25-33. | ||||
Ref 534049 | Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs. Agents Actions.1993 Jan;38(1-2):8-18. | ||||
Ref 534063 | 5-Hydroxyanthranilic acid derivatives as potent 5-lipoxygenase inhibitors. J Antibiot (Tokyo). 1993 May;46(5):705-11. | ||||
Ref 534079 | CGS 26529: the biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action. Inflamm Res. 1995 Aug;44 Suppl 2:S147-8. | ||||
Ref 534187 | Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57. | ||||
Ref 534226 | Selective blockade of leukotriene production by a single dose of the FPL 64170XX 0.5% enema in active ulcerative colitis. Pharmacol Toxicol. 1995 Dec;77(6):371-6. | ||||
Ref 534335 | J Med Chem. 1997 Feb 28;40(5):819-24.Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. | ||||
Ref 534411 | Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52. | ||||
Ref 534446 | Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101. | ||||
Ref 534507 | J Med Chem. 1997 Nov 7;40(23):3773-80.Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. | ||||
Ref 534599 | J Med Chem. 1998 Mar 26;41(7):1124-37.New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations of the dihydrobenzofuran ring. | ||||
Ref 534630 | J Med Chem. 1998 May 21;41(11):1970-9.(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. | ||||
Ref 534759 | ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Inflamm Res. 1998 Oct;47(10):375-83. | ||||
Ref 534862 | N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg Med Chem Lett. 1999 Apr 5;9(7):979-84. | ||||
Ref 534910 | Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7. | ||||
Ref 534984 | Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4. | ||||
Ref 535027 | Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. | ||||
Ref 535071 | A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann Oncol. 2000 Sep;11(9):1165-70. | ||||
Ref 535256 | Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. J Neurosci Res. 2001 Sep 15;65(6):565-72. | ||||
Ref 535369 | The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage. Neurosurgery. 2001 Nov;49(5):1205-12; discussion 1212-3. | ||||
Ref 535517 | Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. J Rheumatol. 2002 Jul;29(7):1446-53. | ||||
Ref 535615 | Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002 Dec 15;64(12):1767-75. | ||||
Ref 535802 | Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil. J Pharmacol Exp Ther. 1992 Aug;262(2):874-82. | ||||
Ref 536189 | Tumour necrosis factor production in a rat airpouch model of inflammation: role of eicosanoids. Agents Actions. 1991 Mar;32(3-4):289-94. | ||||
Ref 536223 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | ||||
Ref 536343 | Characterization and modulation of antigen-induced effects in isolated rat heart. J Cardiovasc Pharmacol. 1991 Oct;18(4):556-65. | ||||
Ref 536489 | Pharmacological nature of nicotine-induced contraction in the rat basilar artery: involvement of arachidonic acid metabolites. Eur J Pharmacol. 2007 Dec 22;577(1-3):109-14. Epub 2007 Aug 14. | ||||
Ref 536518 | Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 1991;34:189-99. | ||||
Ref 536532 | Leukotriene B4/leukotriene B4 receptor pathway is involved in hepatic microcirculatory dysfunction elicited by endotoxin. Shock. 2008 Jul;30(1):87-91. | ||||
Ref 536541 | Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis. 2008 Feb;29(2):371-80. Epub 2007 Nov 21. | ||||
Ref 536548 | Activity and potential role of licofelone in the management of osteoarthritis. Clin Interv Aging. 2007;2(1):73-9. | ||||
Ref 536629 | Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors. Prostaglandins Leukot Essent Fatty Acids. 2008 Feb;78(2):99-108. Epub 2008 Feb 15. | ||||
Ref 536698 | Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World J Gastroenterol. 2008 Apr 28;14(16):2494-500. | ||||
Ref 536714 | Protection of mouse brain from aluminum-induced damage by caffeic acid. CNS Neurosci Ther. 2008 Spring;14(1):10-6. | ||||
Ref 536815 | Anti-inflammatory activity of Acanthus ilicifolius. J Ethnopharmacol. 2008 Oct 30;120(1):7-12. Epub 2008 Jul 25. | ||||
Ref 536829 | Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6. Epub 2008 Aug 22. | ||||
Ref 536892 | Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008 Oct 15;14(20):6525-30. | ||||
Ref 536901 | Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells. J Neurosci Res. 2009 Mar;87(4):991-1001. | ||||
Ref 536917 | Platelets stimulate airway smooth muscle cell proliferation through mechanisms involving 5-lipoxygenase and reactive oxygen species. Platelets. 2008 Nov;19(7):528-36. | ||||
Ref 536971 | The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol. 2009 Mar-Apr;50(3-4):123-31. Epub 2008 Nov 28. | ||||
Ref 537073 | 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009 Mar;19(3):244-7. | ||||
Ref 537169 | 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Mar 23. | ||||
Ref 537200 | Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor. Eur J Pharmacol. 2009 Jun 2;611(1-3):100-6. Epub 2009 Apr 1. | ||||
Ref 537395 | Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J Ethnopharmacol. 2009 Jul 30;124(3):506-12. Epub 2009 May 28. | ||||
Ref 537431 | Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas. Oncogene. 2009 Jul 23;28(29):2690-6. Epub 2009 Jun 8. | ||||
Ref 537655 | Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats. Kidney Int. 1991 May;39(5):920-9. | ||||
Ref 537659 | Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism. Circ Shock. 1990 Nov;32(3):231-42. | ||||
Ref 537662 | Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J Invest Dermatol. 1990 Jul;95(1):50-4. | ||||
Ref 537697 | Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models. Biochim Biophys Acta. 1988 Apr 15;959(3):332-42. | ||||
Ref 537735 | Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo (b)thiophene-2-carboxamide. Arzneimittelforschung. 1988 Mar;38(3):372-8. | ||||
Ref 537748 | Effect of 5-lipoxygenase inhibitor on experimental delayed cerebral vasospasm. Stroke. 1987 Mar-Apr;18(2):512-8. | ||||
Ref 537871 | Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773. Ann N Y Acad Sci. 1994 Nov 15;744:262-73. | ||||
Ref 537895 | Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005. Eur J Pharmacol. 1994 Jun 2;258(1-2):95-102. | ||||
Ref 537907 | Selective inhibition of 5-lipoxygenase attenuates glomerulonephritis in the rat. Kidney Int. 1994 May;45(5):1301-10. | ||||
Ref 537990 | Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam Appl Toxicol. 1996 Sep;33(1):38-48. | ||||
Ref 538006 | Antileukotriene therapy for asthma. Am J Health Syst Pharm. 1996 Dec 1;53(23):2821-30; quiz 2877-8. | ||||
Ref 538009 | Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. Skin Pharmacol. 1996;9(5):307-11. | ||||
Ref 538075 | The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. | ||||
Ref 538079 | Effects of TMK688, a novel anti-allergic drug, on allergic nasal obstruction and exudative responses in sensitized guinea pigs. Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):815-9. | ||||
Ref 538140 | Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein. J Biol Chem. 1998 Dec 4;273(49):32842-7. | ||||
Ref 544446 | Inflammation, Cancer and Oxidative Lipoxygenase Activity are Intimately Linked. Cancers (Basel) 2014 September; 6(3): 1500-1521. | ||||
Ref 550942 | WO patent application no. 2006,1317,37, Method and composition for treating inflammatory disorders. | ||||
Ref 551270 | Design of pyrrolo-1,4-benzoxazine derivatives as inhibitors of 5-lipoxygenase and PAF antagonists with anthihistaminic properties, Bioorg. Med. Chem. Lett. 4(20):2383-2388 (1994). | ||||
Ref 551361 | Cylindol A, a novel biphenyl ether with 5-lipoxygenase inhibitory activity, and a related compound from Imperata Cylindrica. J Nat Prod. 1994 Sep;57(9):1290-3. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.